Clinical Trial Detail

NCT ID NCT02679131
Title To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Belinostat

Age Groups: adult

No variant requirements are available.